Download MendeleySelective Inhibitors of Bacterial t-RNA-(N(1)G37) Methyltransferase (TrmD) That Demonstrate Novel Ordering of the Lid Domain.
Hill, P.J., Abibi, A., Albert, R., Andrews, B., Gagnon, M.M., Gao, N., Grebe, T., Hajec, L.I., Huang, J., Livchak, S., Lahiri, S.D., McKinney, D.C., Thresher, J., Wang, H., Olivier, N., Buurman, E.T.(2013) J Med Chem 56: 7278-7288
- PubMed: 23981144
- DOI: https://doi.org/10.1021/jm400718n
- Primary Citation of Related Structures:
4MCB, 4MCC, 4MCD - PubMed Abstract:
The tRNA-(N(1)G37) methyltransferase (TrmD) is essential for growth and highly conserved in both Gram-positive and Gram-negative bacterial pathogens. Additionally, TrmD is very distinct from its human orthologue TRM5 and thus is a suitable target for the design of novel antibacterials. Screening of a collection of compound fragments using Haemophilus influenzae TrmD identified inhibitory, fused thieno-pyrimidones that were competitive with S-adenosylmethionine (SAM), the physiological methyl donor substrate. Guided by X-ray cocrystal structures, fragment 1 was elaborated into a nanomolar inhibitor of a broad range of Gram-negative TrmD isozymes. These compounds demonstrated no activity against representative human SAM utilizing enzymes, PRMT1 and SET7/9. This is the first report of selective, nanomolar inhibitors of TrmD with demonstrated ability to order the TrmD lid in the absence of tRNA.
Organizational Affiliation:
Departments of Chemistry, ‡Biosciences and §Discovery Sciences, Infection Innovative Medicines Unit, AstraZeneca R&D Boston , 35 Gatehouse Drive, Waltham, Massachusetts 02451, United States.
